Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Express Scripts
McKinsey
AstraZeneca
Johnson and Johnson

Last Updated: June 28, 2022

GENVOYA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Genvoya, and what generic alternatives are available?

Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eleven patents protecting this drug.

This drug has five hundred and five patent family members in fifty-four countries.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch® Generic Entry Outlook for Genvoya

Genvoya was eligible for patent challenges on November 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 6, 2033. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Drug patent expirations by year for GENVOYA
Drug Prices for GENVOYA

See drug prices for GENVOYA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for GENVOYA
Generic Entry Date for GENVOYA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GENVOYA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Canadian Institutes of Health Research (CIHR)Phase 2
St. Michael's Hospital, TorontoPhase 2
CIHR Canadian HIV Trials NetworkPhase 2

See all GENVOYA clinical trials

US Patents and Regulatory Information for GENVOYA

GENVOYA is protected by eleven US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of GENVOYA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting GENVOYA

Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

4-oxoquinoline compound and use thereof as pharmaceutical agent
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Prodrugs of phosphonate nucleotide analogues
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stable crystal of 4-oxoquinoline compound
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Prodrugs of phosphonate nucoleotide analogues
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HIV INFECTION

Modulators of pharmacokinetic properties of therapeutics
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Combination therapy
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Tenofovir alafenamide hemifumarate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stable crystal of 4-oxoquinoline compound
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Tenofovir alafenamide hemifumarate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Modulators of pharmacokinetic properties of therapeutics
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for GENVOYA

International Patents for GENVOYA

When does loss-of-exclusivity occur for GENVOYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 89
Estimated Expiration: See Plans and Pricing

Patent: 50
Estimated Expiration: See Plans and Pricing

Argentina

Patent: 5369
Estimated Expiration: See Plans and Pricing

Australia

Patent: 09242451
Estimated Expiration: See Plans and Pricing

Patent: 10210598
Estimated Expiration: See Plans and Pricing

Patent: 14221210
Estimated Expiration: See Plans and Pricing

Patent: 15200637
Estimated Expiration: See Plans and Pricing

Patent: 16250470
Estimated Expiration: See Plans and Pricing

Patent: 17201473
Estimated Expiration: See Plans and Pricing

Patent: 18267573
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0911871
Estimated Expiration: See Plans and Pricing

Patent: 1008664
Estimated Expiration: See Plans and Pricing

Canada

Patent: 20856
Estimated Expiration: See Plans and Pricing

Patent: 50521
Estimated Expiration: See Plans and Pricing

Chile

Patent: 11001885
Estimated Expiration: See Plans and Pricing

China

Patent: 2123700
Estimated Expiration: See Plans and Pricing

Patent: 2307573
Estimated Expiration: See Plans and Pricing

Patent: 3479584
Estimated Expiration: See Plans and Pricing

Patent: 4940937
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 21225
Estimated Expiration: See Plans and Pricing

Patent: 00187
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0151009
Estimated Expiration: See Plans and Pricing

Patent: 0151357
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 16852
Estimated Expiration: See Plans and Pricing

Patent: 17067
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 96633
Estimated Expiration: See Plans and Pricing

Patent: 93485
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 10010636
Estimated Expiration: See Plans and Pricing

Patent: 11011307
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 1313
Estimated Expiration: See Plans and Pricing

Patent: 2950
Estimated Expiration: See Plans and Pricing

Patent: 0123
Estimated Expiration: See Plans and Pricing

Patent: 1071173
Estimated Expiration: See Plans and Pricing

Patent: 1190125
Estimated Expiration: See Plans and Pricing

Patent: 1491658
Estimated Expiration: See Plans and Pricing

Patent: 1591353
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 96633
Estimated Expiration: See Plans and Pricing

Patent: 93485
Estimated Expiration: See Plans and Pricing

Patent: 06032
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 53670
Estimated Expiration: See Plans and Pricing

Patent: 64737
Estimated Expiration: See Plans and Pricing

Patent: 15679
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 25822
Estimated Expiration: See Plans and Pricing

Patent: 26380
Estimated Expiration: See Plans and Pricing

Israel

Patent: 8614
Estimated Expiration: See Plans and Pricing

Patent: 4227
Estimated Expiration: See Plans and Pricing

Patent: 7417
Estimated Expiration: See Plans and Pricing

Japan

Patent: 11242
Estimated Expiration: See Plans and Pricing

Patent: 22213
Estimated Expiration: See Plans and Pricing

Patent: 11927
Estimated Expiration: See Plans and Pricing

Patent: 25171
Estimated Expiration: See Plans and Pricing

Patent: 11522790
Estimated Expiration: See Plans and Pricing

Patent: 12517432
Estimated Expiration: See Plans and Pricing

Patent: 14012741
Estimated Expiration: See Plans and Pricing

Patent: 14221845
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 2377
Estimated Expiration: See Plans and Pricing

Patent: 10011963
Estimated Expiration: See Plans and Pricing

Patent: 11008289
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 8978
Estimated Expiration: See Plans and Pricing

Patent: 4214
Estimated Expiration: See Plans and Pricing

Peru

Patent: 110994
Estimated Expiration: See Plans and Pricing

Poland

Patent: 96633
Estimated Expiration: See Plans and Pricing

Patent: 93485
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 96633
Estimated Expiration: See Plans and Pricing

Patent: 93485
Estimated Expiration: See Plans and Pricing

San Marino

Patent: 01500266
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 3544
Estimated Expiration: See Plans and Pricing

Patent: 0618
Estimated Expiration: See Plans and Pricing

Patent: 14007744
Estimated Expiration: See Plans and Pricing

Patent: 201609006W
Estimated Expiration: See Plans and Pricing

Patent: 201706215U
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 96633
Estimated Expiration: See Plans and Pricing

Patent: 93485
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1008007
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1645759
Estimated Expiration: See Plans and Pricing

Patent: 1659971
Estimated Expiration: See Plans and Pricing

Patent: 1738325
Estimated Expiration: See Plans and Pricing

Patent: 1784647
Estimated Expiration: See Plans and Pricing

Patent: 110015581
Estimated Expiration: See Plans and Pricing

Patent: 110122729
Estimated Expiration: See Plans and Pricing

Patent: 160093100
Estimated Expiration: See Plans and Pricing

Patent: 160114728
Estimated Expiration: See Plans and Pricing

Spain

Patent: 48886
Estimated Expiration: See Plans and Pricing

Patent: 53897
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 44367
Estimated Expiration: See Plans and Pricing

Patent: 1040142
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 1193
Estimated Expiration: See Plans and Pricing

Patent: 3224
Estimated Expiration: See Plans and Pricing

Uruguay

Patent: 424
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GENVOYA around the world.

Country Patent Number Title Estimated Expiration
Australia 2005225039 See Plans and Pricing
Slovenia 1636190 See Plans and Pricing
New Zealand 594214 TABLETS COMPRISING COBICISTAT, ELVITEGRAVIR, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE FOR COMBINATION THERAPY See Plans and Pricing
Japan 5063554 See Plans and Pricing
Taiwan I248928 See Plans and Pricing
South Korea 100188357 See Plans and Pricing
South Korea 20080064909 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for GENVOYA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1301519 C01301519/01 Switzerland See Plans and Pricing PRODUCT NAME: TENOFOVIRALAFENAMID; REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 65793 01.09.2016
1564210 C01564210/01 Switzerland See Plans and Pricing CHANGE OF ADDRESS OF THE OWNER: JAPAN TOBACCO INC., 1-1, TORANOMON 4-CHOME, MINATO-KU, TOKYO 105-6927, JP
1301519 300803 Netherlands See Plans and Pricing PRODUCT NAME: TENOFOVIRALAFENAMIDE OF EEN ZOUT OF SOLVAAT DAARVAN, MET NAME TENOFOVIRALAFENAMIDEFUMARAAT; NATIONAL REGISTRATION NO/DATE: EU/1/15/1061/002 20151123; FIRST REGISTRATION: EU EU/1/15/1061/001 20151123
3150586 122020000022 Germany See Plans and Pricing PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND EMTRICITABIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/17/1225 20170921
2487163 60/2016 Austria See Plans and Pricing PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE ATAZANAVIR-SULFAT; REGISTRATION NO/DATE: EU/1/15/1025 (MITTEILUNG) 20150715
3150586 132020000000055 Italy See Plans and Pricing PRODUCT NAME: COBICISTAT O UN SALE FARMACOLOGICAMENTE ACCETTABILE O UN SOLVATO DELLO STESSO, DARUNAVIR O UN SALE FARMACOLOGICAMENTE ACCETTABILE O UN SOLVATO DELLO STESSO, IN PARTICOLARE DARUNAVIR ETANOLATO, E EMTRICITABINE O UN SALE FARMACOLOGICAMENTE ACCETTABILE O UN SOLVATO DELLO STESSO(SYMTUZA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1225, 20170925
2487166 93354 Luxembourg See Plans and Pricing PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ALAFENAMIDE DE TENOFOVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE D'ALAFENAMIDE DE TENOFOVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1061
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Medtronic
McKinsey
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.